<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" > <channel> <title>drug patent – Creative Biolabs Blog</title> <atom:link href="https://www.creative-biolabs.com/blog/index.php/tag/drug-patent/feed/" rel="self" type="application/rss+xml" /> <link>https://www.creative-biolabs.com/blog</link> <description>Specialized in providing custom biotechnology and pharmaceutical services</description> <lastBuildDate>Wed, 18 Apr 2018 06:03:41 +0000</lastBuildDate> <language>en-US</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.3.1</generator> <image> <url>https://www.creative-biolabs.com/blog/wp-content/uploads/2020/02/favicon.png</url> <title>drug patent – Creative Biolabs Blog</title> <link>https://www.creative-biolabs.com/blog</link> <width>32</width> <height>32</height> </image> <item> <title>A Quick View of the Global R&D Situation of EGFR Drugs</title> <link>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/</link> <comments>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/#comments</comments> <dc:creator><![CDATA[biolabs]]></dc:creator> <pubDate>Thu, 27 Jul 2017 04:07:59 +0000</pubDate> <category><![CDATA[Antibody Engineering Research]]></category> <category><![CDATA[antibody drug]]></category> <category><![CDATA[biosimiar]]></category> <category><![CDATA[drug patent]]></category> <category><![CDATA[egfr-targeted drug]]></category> <category><![CDATA[Therapeutic Antibody]]></category> <guid isPermaLink="false">http://www.creative-biolabs.com/blog/?p=913</guid> <description><![CDATA[1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total. Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan,<a class="moretag" href="https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/">Read More...</a>]]></description> <content:encoded><![CDATA[<p>1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total.</p> <p>Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan, South Korea, etc.), 80 in clinical application and research stage, and 2 in NDA application.</p> <p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png"><img decoding="async" fetchpriority="high" class="aligncenter size-full wp-image-914" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png" alt="EGFR-targeted drugs" width="590" height="327" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png 590w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1-300x166.png 300w" sizes="(max-width: 590px) 100vw, 590px" /></a></p> <p>2. EGFR-targeted drugs are mainly small molecule inhibitors.</p> <p>Molecular targeting drugs developed for EGFR are divided into two major categories:</p> <p>1) There are 18 monoclonal antibodies, such as <strong><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://www.creativebiolabs.net/Cetuximab-32082.htm" target="_blank">cetuximab</a></span></strong> and <strong><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://www.creativebiolabs.net/Panitumumab-22418.htm" target="_blank">panitumumab</a></span></strong>. They can bind to EGFR extracellular region and block ligand-dependent EGFR activation.</p> <p>2) There are 68 small molecule inhibitors, including small molecule multi-target receptor tyrosine kinase (RTKs) Inhibitors and small molecule tyrosine kinase inhibitors (EGFR-TKls), which can inhibit tyrosine kinase’s activity in EGFR intracellular region.</p> <p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png"><img decoding="async" class="aligncenter size-full wp-image-916" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png" alt="Small molecule inhibitors" width="380" height="219" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png 380w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21-300x173.png 300w" sizes="(max-width: 380px) 100vw, 380px" /></a></p> <p>3. 9 EGFR small molecule inhibitor drugs are approved.</p> <p>1) AstraZeneca has 3 approved drugs, occupying one third of the global market.</p> <p>2) The approved EGFR small molecule inhibitors are mainly sued for the treatment of non-small cell lung cancer.</p> <p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png"><img decoding="async" class="aligncenter size-full wp-image-917" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png" alt="9 EGFR small molecule inhibitor drugs are approved" width="746" height="483" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png 746w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3-300x194.png 300w" sizes="(max-width: 746px) 100vw, 746px" /></a></p> <p>3) In the United States, there are 8 approved EGFR small molecule inhibitor drugs which have patent protection. Gefitinib is confronting with patent cliff.</p> <p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png"><img decoding="async" loading="lazy" class="aligncenter size-full wp-image-918" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png" alt="8 approved EGFR small molecule inhibitor drugs" width="573" height="334" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png 573w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4-300x175.png 300w" sizes="(max-width: 573px) 100vw, 573px" /></a></p> <p> </p> <p>4. 4 EGFR-targeted monoclonal antibodies are approved.</p> <p>1) Antibody class EGFR-targeted drugs are mainly used for the treatment of rectal cancer, head and neck cancer.</p> <p>2) Eli Lilly has 2 approved drugs, dominating the EGFR monoclonal antibody market.</p> <p>3) Cetuximab is the champion of the year, with sales twice as much as panitumumab of the same indication.</p> <p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png"><img decoding="async" loading="lazy" class="aligncenter size-full wp-image-919" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png" alt="4 EGFR-targeted monoclonal antibodies are approved." width="693" height="481" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png 693w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6-300x208.png 300w" sizes="(max-width: 693px) 100vw, 693px" /></a></p> <p><strong>Notes:</strong> The global sales showed in the histogram are the original sales of the relevant company. The above data was retrieved on July 12, 2017.</p> <p> </p> <p> </p> <p> </p> <p> </p> ]]></content:encoded> <wfw:commentRss>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/feed/</wfw:commentRss> <slash:comments>56</slash:comments> </item> </channel> </rss>